- Home
- ABSI vs MLTX Comparison
ABSI vs MLTX Comparison
Compare ABSI & MLTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ABSI
- MLTX
- Stock Information
- Founded
- ABSI 2011
- MLTX 2021
- Country
- ABSI United States
- MLTX Switzerland
- Employees
- ABSI N/A
- MLTX N/A
- Industry
- ABSI Biotechnology: Pharmaceutical Preparations
- MLTX Biotechnology: Pharmaceutical Preparations
- Sector
- ABSI Health Care
- MLTX Health Care
- Exchange
- ABSI Nasdaq
- MLTX Nasdaq
- Market Cap
- ABSI 505.4M
- MLTX 535.3M
- IPO Year
- ABSI 2021
- MLTX N/A
- Fundamental
- Price
- ABSI $3.79
- MLTX $8.65
- Analyst Decision
- ABSI Strong Buy
- MLTX Buy
- Analyst Count
- ABSI 6
- MLTX 9
- Target Price
- ABSI $7.98
- MLTX $37.63
- AVG Volume (30 Days)
- ABSI 5.8M
- MLTX 8.4M
- Earning Date
- ABSI 11-11-2025
- MLTX 11-06-2025
- Dividend Yield
- ABSI N/A
- MLTX N/A
- EPS Growth
- ABSI N/A
- MLTX N/A
- EPS
- ABSI N/A
- MLTX N/A
- Revenue
- ABSI $4,138,000.00
- MLTX N/A
- Revenue This Year
- ABSI $41.73
- MLTX N/A
- Revenue Next Year
- ABSI $384.22
- MLTX N/A
- P/E Ratio
- ABSI N/A
- MLTX N/A
- Revenue Growth
- ABSI 27.32
- MLTX N/A
- 52 Week Low
- ABSI $2.01
- MLTX $5.95
- 52 Week High
- ABSI $6.33
- MLTX $62.75
- Technical
- Relative Strength Index (RSI)
- ABSI 73.13
- MLTX 21.82
- Support Level
- ABSI $2.48
- MLTX $6.56
- Resistance Level
- ABSI $3.70
- MLTX $7.48
- Average True Range (ATR)
- ABSI 0.24
- MLTX 2.38
- MACD
- ABSI 0.13
- MLTX -5.00
- Stochastic Oscillator
- ABSI 95.81
- MLTX 4.75
About ABSI Absci Corporation
Absci Corp is the Artificial intelligence powered synthetic biology company unlocking the potential of proteins as the next generation of therapeutics. It enables the creation of novel biologics by unifying biologic drug discovery and cell line development into one simultaneous process.
About MLTX MoonLake Immunotherapeutics
MoonLake Immunotherapeutics is a clinical-stage biotechnology company advancing therapies to address unmet needs in inflammatory skin and joint diseases. The company is focused on the development of SLK, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody that has the potential, based on response levels seen in clinical trials, to drive disease modification in dermatology and rheumatology patients.